BRENUS PHARMA

French Private Biotechnology aims to become leader in allogeneic immunotherapy thanks to its innovative, unique patented platform: Stimulated Tumor Cell (STC). We develop an allogeneic platform designed to generate first in class therapeutic cancer vaccine and stimulate patients’ immune system by fighting immune tolerance, chemoresistance and anticipate tumor microenvironment plasticity which are the 3 causes of treatment failure.

Our approach is based on a proprietary discovery platform named STC, the lead candidate STC-1010, is based on metastatic colorectal cancer (mCRC) tumor cells.

The STC therapy is the first approach to offer a response to the 3 major challenges limiting immunotherapies approaches to target treatments resistances: representativity, antigenicity and immunogenicity.

The STC therapy has a very significant potential for generating new classes of immunotherapies and will be the only one to combine in the same treatment, technologies which have proven their effectiveness separately and which respond to the known limits of current treatments.

The STC Therapy is a complete off-the shelf approach based on allogeneic cell lines from well characterized tumor bank (ie ATCC,…) allowing a cost, production time and supply controlled and provide the treatment to an important population.

An experienced team backed by Top KOL in immuno oncology in EU or US has conducted very positive efficacy data :

In vitro and animal models of colorectal cancer (CRC) to enter Phase 1/2 trial in 2023 in EU and US in 1st line mCRC in combination with SOC. Pre IND meeting with FDA and SA with European agency (Belgium) has been done and we are scaling up our manufacturing process to supply large amount of doses. New asset development through new indication and combination opportunities with our STC platform are investigated.